看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -2.6x - -2.9x | -2.8x |
| Selected Fwd EBIT Multiple | -7.4x - -8.2x | -7.8x |
| Fair Value | €0.47 - €0.52 | €0.49 |
| Upside | 85.4% - 105.0% | 95.2% |
| Benchmarks | Ticker | Full Ticker |
| Genscript Biotech Corporation | GNNS.F | PINC:GNNS.F |
| Johnson & Johnson | JNJ | NYSE:JNJ |
| AbbVie Inc. | ABBV | NYSE:ABBV |
| Medpace Holdings, Inc. | MEDP | NasdaqGS:MEDP |
| Quanterix Corporation | QTRX | NasdaqGM:QTRX |
| ImmunoPrecise Antibodies Ltd. | TQB | DB:TQB |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| GNNS.F | JNJ | ABBV | MEDP | QTRX | TQB | ||
| PINC:GNNS.F | NYSE:JNJ | NYSE:ABBV | NasdaqGS:MEDP | NasdaqGM:QTRX | DB:TQB | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | 1.2% | 5.2% | 28.6% | NM- | NM- | |
| 3Y CAGR | NM- | 1.6% | -2.5% | 31.0% | NM- | NM- | |
| Latest Twelve Months | -64.6% | -4.4% | 8.0% | 28.7% | -21.1% | -14.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -53.8% | 26.6% | 34.8% | 18.5% | -48.5% | -68.2% | |
| Prior Fiscal Year | 4.7% | 28.0% | 32.5% | 17.9% | -33.5% | -121.7% | |
| Latest Fiscal Year | 1.6% | 25.4% | 32.5% | 21.2% | -36.1% | -57.5% | |
| Latest Twelve Months | 1.6% | 25.4% | 32.9% | 21.2% | -36.1% | -61.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 5.31x | 4.31x | 7.05x | 3.89x | -0.20x | 1.23x | |
| EV / LTM EBITDA | 45.1x | 12.8x | 14.8x | 17.3x | 0.6x | -2.4x | |
| EV / LTM EBIT | 340.3x | 16.9x | 21.4x | 18.4x | 0.6x | -2.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 0.6x | 18.4x | 340.3x | ||||
| Historical EV / LTM EBIT | -42.4x | -9.0x | -3.2x | ||||
| Selected EV / LTM EBIT | -2.6x | -2.8x | -2.9x | ||||
| (x) LTM EBIT | (15) | (15) | (15) | ||||
| (=) Implied Enterprise Value | 39 | 41 | 43 | ||||
| (-) Non-shareholder Claims * | (0) | (0) | (0) | ||||
| (=) Equity Value | 39 | 41 | 43 | ||||
| (/) Shares Outstanding | 53.4 | 53.4 | 53.4 | ||||
| Implied Value Range | 0.73 | 0.77 | 0.81 | ||||
| FX Rate: CAD/EUR | 1.6 | 1.6 | 1.6 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.47 | 0.49 | 0.52 | 0.25 | |||
| Upside / (Downside) | 85.4% | 95.2% | 105.0% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | GNNS.F | JNJ | ABBV | MEDP | QTRX | TQB | |
| Enterprise Value | (73) | 383,855 | 404,478 | 8,396 | (29) | 21 | |
| (+) Cash & Short Term Investments | 621 | 38,781 | 5,555 | 441 | 289 | 13 | |
| (+) Investments & Other | 3,790 | 1,258 | 0 | 0 | 1 | 0 | |
| (-) Debt | (724) | (52,252) | (68,019) | (150) | (37) | (13) | |
| (-) Other Liabilities | (2) | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,612 | 371,642 | 342,014 | 8,687 | 224 | 21 | |
| (/) Shares Outstanding | 2,778.3 | 2,406.1 | 1,769.0 | 28.7 | 38.8 | 53.4 | |
| Implied Stock Price | 1.30 | 154.46 | 193.34 | 302.25 | 5.77 | 0.39 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.56 | |
| Implied Stock Price (Trading Cur) | 1.30 | 154.46 | 193.34 | 302.25 | 5.77 | 0.25 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.56 | |